19853-79-3Relevant articles and documents
Highly selective hydrogenation of aromatic chloronitro compounds to aromatic chloroamines with ionic-liquid-like copolymer stabilized platinum nanocatalysts in ionic liquids
Yuan, Xiao,Yan, Ning,Xiao, Chaoxian,Li, Changning,Fei, Zhaofu,Cai, Zhipeng,Kou, Yuan,Dyson, Paul J.
, p. 228 - 233 (2010)
Platinum nanoparticles (PtNPs stabilized by an ionic-liquid-like-copolymer (IP) immobilized in various ionic liquids (ILs)) effectively catalyze the selective hydrogenation of aromatic chloronitro compounds to aromatic chloroamines, a reaction of considerable commercial significance. The preparation of 2,4-dichloro-3-aminophenol (DAP) has been primarily studied due to its important industrial applications. DAP is usually prepared from 2,4-dichloro-3-nitrophenol (DNP) by reduction with hydrogen using Ni- or Pt-based catalysts. Compared to reactions in molecular (organic) solvents, the ILs system provides superior selectivity with functionalized ILs containing an alcohol group demonstrating the best recyclability, and ultimately achieving a turnover number of 2025 which is 750 fold higher than Raney nickel catalyst. A universal catalyst-ionic liquid system for the conversion of aromatic chloronitro compounds to aromatic chloroamines was also established. TEM, XPS, IR spectroscopy were used to characterize the morphology of the nanocatalysts allowing their structure to be correlated to their activity.
2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS
-
Page 46, (2010/02/07)
Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
IMIDAZO [1,2-A] PYRIDINES AND THEIR PHARMACEUTICAL USE
-
, (2008/06/13)
The invention relates to novel bradykinin antagonists of the formula: STR1 wherein R 1 is halogen,R 2 and R 3 are each hydrogen, lower alkyl, halo(lower)alkyl or acyl,R 4 is aryl having suitable substituent(s), or a heterocyclic group optionally having suitable substituent(s),Q is O or N--R 11, in which R 11 is hydrogen or acyl, andA is lower alkylene,and pharmaceutically acceptable salts thereof.